A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Public ClinicalTrials.gov record NCT05139017. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
Study identification
- NCT ID
- NCT05139017
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 290 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Gemcitabine Drug
- Granulocyte Colony-Stimulating Factor (G-CSF) Drug
- Oxaliplatin Drug
- Rituximab Biological
- Zilovertamab vedotin Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2022
- Primary completion
- Sep 23, 2027
- Completion
- Sep 23, 2027
- Last update posted
- May 7, 2026
2022 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175) | Glendale | Arizona | 85304 | Recruiting |
| Beverly Hills Cancer Center ( Site 0184) | Beverly Hills | California | 90211 | Recruiting |
| Bass Medical Group ( Site 0166) | Walnut Creek | California | 94598 | Recruiting |
| Innovative Clinical Research Institute ( Site 0122) | Whittier | California | 90603 | Completed |
| Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163) | Boca Raton | Florida | 33486 | Recruiting |
| Clermont Oncology Center ( Site 0174) | Clermont | Florida | 34711 | Recruiting |
| BRP-Hialeah Hospital ( Site 0182) | Hialeah | Florida | 33013 | Recruiting |
| Illinois Cancer Specialists ( Site 8000) | Niles | Illinois | 60714 | Recruiting |
| Saint Elizabeth Medical Center Edgewood ( Site 0165) | Edgewood | Kentucky | 41017 | Recruiting |
| University of Kentucky Chandler Medical Center ( Site 0158) | Lexington | Kentucky | 40536 | Recruiting |
| Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133) | Louisville | Kentucky | 40207 | Recruiting |
| University of Maryland ( Site 0123) | Baltimore | Maryland | 21201 | Recruiting |
| Dana-Farber Cancer Institute-Lymphoma ( Site 0111) | Boston | Massachusetts | 02215 | Recruiting |
| University of Massachusetts Medical School ( Site 0119) | Worcester | Massachusetts | 01655 | Recruiting |
| Corewell Health ( Site 0162) | Grand Rapids | Michigan | 49503 | Recruiting |
| St. Vincent Frontier Cancer Center-Research ( Site 0108) | Billings | Montana | 59102 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188) | Grand Island | Nebraska | 68803 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177) | Omaha | Nebraska | 68130 | Recruiting |
| Comprehensive Cancer Centers of Nevada ( Site 0168) | Las Vegas | Nevada | 89169 | Recruiting |
| Atlantic Health System ( Site 0116) | Morristown | New Jersey | 07960 | Completed |
| Presbyterian Rust Jorgensen Cancer ( Site 9506) | Rio Rancho | New Mexico | 87124 | Recruiting |
| New York Medical College ( Site 0113) | Valhalla | New York | 10595 | Recruiting |
| Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156) | Nashville | Tennessee | 37232 | Completed |
| Blue Ridge Cancer Care ( Site 0169) | Roanoke | Virginia | 24014 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05139017, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05139017 live on ClinicalTrials.gov.